The DOI matches its Crossref record.
Mechanisms of immunotherapeutic intervention by anti-CD40L (CD154) antibody in an animal model of multiple sclerosis
Open accessAbstract
Relapsing experimental autoimmune encephalomyelitis (R-EAE) in the SJL mouse is a Th1-mediated autoimmune demyelinating disease model for human multiple sclerosis and is characterized by infiltration of the central nervous system (CNS) by Th1 cells and macrophages. Disease relapses are mediated by T cells specific for endogenous myelin epitopes released during acute disease, reflecting a critical role for epitope spreading in the perpetuation of chronic central CNS pathology. We asked whether blockade of the CD40-CD154 (CD40L) costimulatory pathway could suppress relapses in mice with established R-EAE. Anti-CD154 antibody treatment at either the peak of acute disease or during remission effectively blocked clinical disease progression and CNS inflammation. This treatment blocked Th1 differentiation and effector function rather than expansion of myelin-specific T cells. Although T-cell proliferation and production of interleukin (IL)-2, IL-4, IL-5, and IL-10 were normal, antibody treatment severely inhibited interferon-gamma production, myelin peptide-specific delayed-type hypersensitivity responses, and induction of encephalitogenic effector cells. Anti-CD154 antibody treatment also impaired the expression of clinical disease in adoptive recipients of encephalitogenic T cells, suggesting that CD40-CD154 interactions may be involved in directing the CNS migration of these cells and/or in their effector ability to activate CNS macrophages/microglia. Thus, blockade of CD154-CD40 interactions is a promising immunotherapeutic strategy for treatment of ongoing T cell-mediated autoimmune diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
van Kooten, C., & Banchereau, J. (2000) · Journal of Leukocyte Biology · doi:10.1002/jlb.67.1.2 · Cited by 1,404
Epitope spreading in immune-mediated diseases: implications for immunotherapy
Vanderlugt, C. L., & Miller, S. D. (2002) · Nature Reviews Immunology · doi:10.1038/nri724 · Cited by 950
Self-citationThe microglial "activation" continuum: from innate to adaptive responses
Town, T., Nikolic, V., & Tan, J. (2005) · Journal of Neuroinflammation · doi:10.1186/1742-2094-2-24 · Cited by 456
Co-stimulatory and Co-inhibitory Pathways in Autoimmunity
Zhang, Q., & Vignali, D. A. A. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.017 · Cited by 296
Diab, A., Deng, C., Smith, J. D., Hussain, R. Z., Phanavanh, B., Lovett-Racke, A. E., Drew, P. D., & Racke, M. K. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.5.2508 · Cited by 291
CD40 and autoimmunity: The dark side of a great activator
Peters, A. L., Stunz, L. L., & Bishop, G. A. (2009) · Seminars in Immunology · doi:10.1016/j.smim.2009.05.012 · Cited by 270
Aging‐dependent changes of microglial cells and their relevance for neurodegenerative disorders
Von Bernhardi, R., Tichauer, J. E., & Eugenín, J. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06537.x · Cited by 258
Inflammation in multiple sclerosis: the good, the bad, and the complex
Martino, G., Adorini, L., Rieckmann, P., Hillert, J., Kallmann, B., Comi, G., & Filippi, M. (2002) · The Lancet Neurology · doi:10.1016/s1474-4422(02)00223-5 · Cited by 142
Innate Immune Response Gene Expression Profiles of N9 Microglia Are Pathogen-Type Specific
McKimmie, C. S., Roy, D., Forster, T., & Fazakerley, J. K. (2006) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.03.012 · Cited by 51
Duarte, J., Carrié, N., Oliveira, V. G., Almeida, C., Agua-Doce, A., Rodrigues, L., Simas, J. P., Mars, L. T., & Graca, L. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1201269 · Cited by 13
Metadata
- Authors
- Howard, L. M., Miga, A. J., Vanderlugt, C. L., Canto, M. C. D., Laman, J. D., Noelle, R. J., & Miller, S. D.
- Venue
- Journal of Clinical Investigation
- Published
- 1999-01-15
- Volume
- 103
- Issue
- 2
- Pages
- 281-290
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2100640696
- Cited by
- 217
- References
- 0
- FWCI
- 14.43
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.